Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes

Vaccine

Volumn 31, Issue 6, 2013, Pages 960-966

  Ciruela, Pilar ^a   Soldevila, Núria ^b   Hernández, Sergi ^a   Selva, Laura ^c   de Sevilla, Mariona F ^c   García García, Juan José ^c   Moraga, Fernando ^d   Planes, Ana María ^d   Muñoz Almagro, Carmen ^c   Domínguez, Angela ^b,e  

^a AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Invasive pneumococcal disease; Penicillin nonsusceptible; Pneumococcal conjugate vaccine; Risk factors; Streptococcus pneumoniae

Indexed keywords

PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CHILD; COMMUNITY; DAY CARE; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOCIAL ASPECT; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; RISK FACTORS; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84872601191     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.102     Document Type: Article

References (39)

1. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
2. Rückinger S., van der Linden M., Reinert R., et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27:4136-4141.
3. Harboe Z., Valentiner-Branth P., Benfield T., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish childhood immunization programme. Vaccine 2010, 28:2642-2647.
4. Centers for Disease Control and Prevention (CDC) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897.
5. Centers for Disease Control and Prevention (CDC) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57:144-148.
6. Blanco A., Gimenez F., Asensi F., et al. Vaccination schedule of the Spanish association of pediatrics: recommendations 2004. Ann Pediatr (Barc) 2004, 60:468-472.
7. American Academy of Pediatrics 2009 report of the committee on infectious diseases 2009, American Academy of Pediatrics, Elk Grove Village. 28th ed.
8. Muñoz-Almagro C., Jordan I., Gene A., et al. Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
9. Salleras L., Dominguez A., Ciruela P., et al. Changes in serotypes causing invasive pneumococcal disease (2005-2007 vs 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin Microbiol Infect 2009, 15:997-1001.
10. Salleras L., Dominguez A., Ciruela P., et al. Impact of 7-valent pneumococcal conjugate vaccination in a population with low to intermediate vaccination levels. Enferm Infecc Microbiol Clin 2009, 27:275-277.
11. Levine O.S., Farley M., Harrison L.H., et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999, 103:E28.
12. Gessner B.D., Ussery X.T., Parkinson A.J., et al. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age. Pediatr Infect Dis J 1995, 14:123-128.
13. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors and strategies for prevention. Semin Respir Crit Care Med 2009, 30:189-209.
14. Musher D.M. Streptococcus pneumoniae. Infectious diseases. Principles and practice 2002, 2582-2604. Editorial Médica Panamericana, Buenos Aires. G.L. Mandell, J.E. Bennett, R. Dalin (Eds.).
15. Special Eurobarometro 338. Antimicrobial resistance. Available from: http://ec.europa.eu/health/antimicrobial_resistance/docs/ebs_338_en.pdf Data; November-December 2009 [accessed 14.05.11].
16. Muñoz-Almagro C., Ciruela P., Esteva C., et al. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect 2011, 63:151-162.
17. Domínguez A., Ciruela P., García-García J.J., et al. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months: a matched case-control study. Vaccine 2011, 29:9020-9025.
18. Statistical Institute of Catalonia. Available from: http://www.idescat.cat/cat/poblacio/poblestructura.html [accessed 04.06.11].
19. Informe del registre del conjunt minim de dades (CMBD). Servei Català de la Salut. Generalitat de Catalunya. Available from: http://www10.gencat.net/catsalut/cat/prov_cmbdpublicacions.htm; December, 2010 [accessed 04.06.11].
20. Fenoll A., Jado I., Vicioso D., et al. Dot blot assay for the serotyping of pneumococci. J Clin Microbiol 1997, 35:764-766.
21. Tarragó D., Fenoll A., Sanchez-Tatay D., et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. Clin Microbiol Infect 2008, 14:828-834.
22. National Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. CLSI document M100e-S18 2008, Clinical and Laboratory Standard Institute, Wayne, PA, ISBN: 1-5-56238-653-0.
23. Office of Population Censuses and Surveys Classification of occupations 1980, HMSO, London.
24. Vestrheim D., Lovoll O., Aaberge I., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26:3277-3281.
25. Aaberge I. Experience with pneumococcal conjugate vaccine in Norway. Exp Rev Vaccines 2009, 8:159-165.
26. Lepoutre A., Varon E., Georges S., et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008, 13.
27. Pilishvili T., Zell E.R., Farley M.M., et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010, 126:e9-e17.
28. De Sevilla M.F., Garcia-Garcia J.J., Esteva C., et al. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine. Pediatr Infect Dis J 2012, 31:124-128.
29. Kaplan S.L., Barson W.J., Lin P.L., Stovall S.H., Bradley J.S., Tan T.Q., et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010, 125:429-436.
30. Takala A.K., Jero J., Kela E., et al. Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA 1995, 273:859-864.
31. Kim P.E., Musher D.M., Glezen W.P., et al. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis 1996, 22:100-106.
32. Ampofo K., Bender J., Sheng X., et al. Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection. Pediatrics 2008, 122:229-237.
33. Fainstein V., Musher D.M., Cate T.R. Bacterial adherence to pharyngeal cells during viral infection. J Infect Dis 1980, 141:172-176.
34. O'Dempsey T.J.D., Mcardle T.F., Morris J., et al. A study of risk factors for pneumococcal disease among children in a rural area of west Africa. Int J Epidemiol 1996, 25:885-893.
35. Pereiró I., Díez-Domingo J., Segarra L., Ballester A., Albert A., Morant A. Risk factors for invasive disease among children in Spain. J Infect 2004, 48:320-329.
36. Haddbad M.B., Porucznik C.A., Joyce K.E., et al. Risk factors for pediatric invasive pneumococcal disease in the intermountain west, 1996-2002. Ann Epidemiol 2008, 18:139-146.
37. Lee C., Middaugh N.A., Howie S., et al. Association of secondhand smoke exposure with pediatric invasive bacterial disease and bacterial carriage: a systematic review and meta-analysis. PLoS Medicine 2010, 7:1-14.
38. Hjuler T., Wohlfahrt J., Simonsen J., et al. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis 2007, 44:1051-1056.
39. Givon-Lavi N., Fraser D., Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003, 22:524-532.